The grades of three pharmaceutical stocks are better this week, according to the Portfolio Grader database. Every one of these stocks has an “A” (“strong buy”) or “B” overall (“buy”) rating.
Watson Pharmaceuticals (WPI) is making headway this week, with the company’s rating improving to an A (“strong buy”) from a B (“buy”) last week. Watson develops, manufactures, markets, sells and distributes pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of WPI stock.
BioDelivery Sciences International, Inc. (BDSI) is bumping up its rating from a C (“hold”) to a B (“buy”) this week. BioDelivery Sciences is a specialty pharmaceutical company that is utilizing licensed and owned proprietary drug delivery technologies to develop and commercialize new formulations of proven therapeutics. Shares of BDSI have increased 32.8% over the past month, better than the 1.3% decrease the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of BDSI stock.
Repros Therapeutics (RPRX) is seeing ratings go up from a C last week to a B this week. Repros Therapeutics is a development stage biopharmaceutical company focusing on the development of oral small molecule drugs for major unmet medical needs. For more information, get Portfolio Grader’s complete analysis of RPRX stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.